歌礼制药-B(01672)公布，2025年12月19日耗资约255.86万港元回购20万股股份。 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 歌禮製藥有限公司 呈交日期： 2025年12月19日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 01672 | 說明 | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | | 佔有關事 ...

Group 1: Pharmaceutical Sector - The innovation drug sector is expected to be the main focus, with particular attention on small nucleic acid technology and its accelerated development by 2026 [1][2] - The pharmaceutical industry is driven by supply creating demand, with significant trends observed from 2018 to 2024, including breakthroughs in PD-1, ADC technology, and new generation immunotherapy [2] - Key companies to watch in the pharmaceutical sector include Heng Rui Medicine, Hansoh Pharmaceutical, China National Pharmaceutical Group, and others involved in small nucleic acid and weight loss drug development [2] Group 2: CXO and Upstream Life Sciences - The CXO sector is expected to see continued improvement in fundamentals and valuation recovery, with a focus on companies like WuXi AppTec and Kanglong Chemical [3] - Upstream life sciences are benefiting from improved domestic research conditions, with companies like BGI Genomics and Bidu Pharmaceutical showing positive performance trends [3] - The raw material drug sector is entering a bottom price range, with companies that have quality clients and orders likely to see improved profit margins [3] Group 3: Medical Devices - The medical device sector is anticipated to benefit from improved hospital demand and inventory optimization, with a potential turning point in 2026 [4] - High-value consumables are expected to gain from collective procurement, enhancing domestic production capabilities [4] - Key players in the medical device sector include Mindray Medical, United Imaging Healthcare, and others [4] Group 4: Healthcare Consumption - The healthcare service sector is under pressure in 2025, but a mild recovery is expected in 2026, particularly in essential medical services and products [5] - Traditional Chinese medicine is projected to stabilize and grow, with a focus on OTC and prescription drug innovations [5] - The pharmacy sector is experiencing increased concentration due to regulatory changes, with companies like Yifeng Pharmacy and Dazhong Pharmacy showing improved performance [5]

Group 1 - The article reports on share buybacks conducted by various companies on December 18, 2025, with Tencent Holdings leading in both the number of shares repurchased and the total amount spent [1] - Tencent Holdings repurchased 1.055 million shares for a total of 636 million yuan, representing 1.030% of its total share capital for the year [2] - Other notable companies involved in the buyback include Xiaomi Group, which repurchased 3.75 million shares for 151 million yuan, and China National Petroleum Corporation, which repurchased 254,000 shares for 116.38 million yuan [3] Group 2 - The total number of shares repurchased by companies varied significantly, with China National Petroleum Corporation having a cumulative buyback of 230 million shares, which is 0.190% of its total share capital [3] - Companies like IGG and VITASOY also participated, with IGG repurchasing 182,000 shares for 68.49 million yuan and VITASOY repurchasing 122,000 shares for 77.94 million yuan [3] - The buyback activity reflects a strategic move by these companies to enhance shareholder value and manage their capital structure effectively [1][2]

回购日期回购均价回购股数回购金额本年累计回购股数2025-12-1812.69320.00万253.86万862.60万2025- 12-1713.00620.00万260.12万842.60万2025-12-1613.04920.00万260.99万822.60万2025-12-1214.57930.00万 437.38万802.60万2025-12-0412.925162.00万2093.89万772.60万2025-12-0312.196130.60万1592.75万610.60 万2025-11-059.24010.00万92.40万480.00万2025-10-319.66320.00万193.27万470.00万2025-10-289.18910.00 万91.89万450.00万2025-10-279.70010.00万97.00万440.00万2025-10-239.01520.00万180.30万430.00万 2025-10-229.26510.00万92.65万410.00万2025-10-179.15210.00万91.53万400.00万2025-10-159.48710.00万 9 ...

歌礼制药-B(01672)发布公告，于2025年12月18日斥资253.86万港元回购20万股。 ...

智通财经APP讯，歌礼制药-B(01672)发布公告，于2025年12月18日斥资253.86万港元回购20万股。 ...

格隆汇12月18日丨歌礼制药-B(01672.HK)发布公告，2025年12月18日耗资253.9万港元回购20万股，回 购价格每股12.49-12.8港元。 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 歌禮製藥有限公司 呈交日期： 2025年12月18日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 01672 | 說明 | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | | 佔有關事 ...

格隆汇12月17日丨歌礼制药-B(01672.HK)发布公告，2025年12月17日耗资260.12万港元回购20万股，回 购价格每股12.55-13.17港元。 ...